Trials
Ongoing trials
All Multiple Myeloma patients including smoldering Multiple Myeloma
Targovax: A phase 1/2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high risk smoldering multiple myeloma, or multiple myeloma, and evidence of measurable disease following ≥ 1 line of treatment
Smoldering Multiple Myeloma:
EMN34 (ERASMM): A multi-center, open-label, phase 2 study of elranatamab in patients with high-risk smoldering multiple myeloma
Newly Diagnosed Multiple Myeloma
REMNANT: The Relapse from MRD negativity as indication for treatment (REMNANT) study- A randomized, open label two-part (phase II and III) to assess whether earlier treatment of relapse, based on Measurable Residual Disease (MRD) prolongs progression free and overall survival and improves quality of life for myeloma patients
CARTITUDE-6: A phase 3 randomized study comparing daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by ciltacabtagene autoleucel versus daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) followed by autologous stem cell transplant (ASCT) in participants with newly diagnosed multiple myeloma who are transplant eligible
MajesTEC-7: A phase 3 randomized study comparing teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy
TALTEC: A phase 2 study measuring MRD negativity after bispecific T-cell redirectors talquetamab and teclistamab consolidation as part of first line treatment in transplant eligible multiple myeloma patients
MagnetisMM-7: A phase 3 randomised study comparing elranatamab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma patients
SHIELD: Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma
Relapsed/Refractory Multiple Myeloma
SUCCESSOR-2: A randomized phase 3 study to evaluate mezigdomide in combination with carfilzomib and dexamethasone (MEZiKd) versus carfilzomib and dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma
ACT: Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma
CA057-003: Phase 1b/2a study to evaluate mezigdomide in combination with other treatments in relapsed or refractory multiple myeloma
Cevostamab: A phase 1b, open-label, multicenter dose-escalation study to evaluate the safety, pharmacokinetics, and activity of xmab24306 in combination with cevostamab in patients with relapsed/refractory multiple myeloma
Impress: A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. Ceritinib is investigated in triple-exposed multiple myeloma patients with high LTK expression